SIM 235
Alternative Names: SIM 0235; SIM 1811-03; SIM-235Latest Information Update: 28 Apr 2025
At a glance
- Originator Simcere Pharmaceutical Group; Simcere Zaiming
- Developer Simcere Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cutaneous T-cell lymphoma; Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (Parenteral, Injection)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (Parenteral, Injection)
- 20 Oct 2023 Adverse events and pharmacokinetic data from a phase I trial in Cutaneous T-cell lymphoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)